STAAR Surgical Boston Consulting Group Matrix
See the Bigger Picture
Curious where STAAR Surgical’s products land — Stars, Cash Cows, Dogs, or Question Marks? This preview scratches the surface; the full BCG Matrix maps each product to its quadrant with data-backed reasoning and clear strategic moves. Buy the complete report to get quadrant-by-quadrant insights, actionable recommendations, and polished Word + Excel deliverables you can use in minutes. Grab the full matrix and stop guessing—plan where to invest, divest, or double down with confidence.
Stars
EVO Visian ICL (Myopia)
EVO Visian ICL is STAAR Surgical’s flagship growth engine in refractive surgery, capturing strong consumer demand for LASIK alternatives and driving double-digit unit growth in 2024; uptake is highest across APAC where the lens holds a dominant position in key centers and is rapidly expanding globally. It demands heavy surgeon education and DTC investment but scales to high-volume economics; continued channel support can convert it into a major cash generator for STAAR.
Toric EVO ICL (Astigmatism)
Leader positioning in the rapidly expanding astigmatism segment: with clinically significant astigmatism present in roughly 30% of adults, Toric EVO ICL meets strong demand as practices chase cleaner refractive outcomes and fewer enhancements. Adoption curves steepen where surgeon training and inventory are optimized; implementation remains marketing- and logistics-intensive, but operational scale is achievable as procedures concentrate in high-volume centers.
ICL Franchise in China and wider APAC
ICL franchise in China and wider APAC sits in a high-growth corridor driven by refractive demand—myopia prevalence exceeds 50% in Chinese adults and reaches 80–90% in school-aged cohorts—boosting surgeon advocacy and referral flywheels. Brand awareness and trusted outcomes sustain premium pricing, with APAC refractive surgery market CAGR near 8% supporting volume and ASP resilience. Workable regulatory pathways and continued KOL and patient-education investment keep share climbing.
U.S. EVO ICL ramp post-approval
Post-approval U.S. ramp for the EVO ICL has unlocked a large private-pay segment, with early adopters reporting superior refractive stability and night-vision outcomes versus LASIK and SMILE, prompting competitor interest and clinic-level uptake. Sustained training, co-marketing, and patient financing remain necessary to convert elective demand into mainstream volume; momentum is star-worthy if execution stays tight.
- Regulatory tailwind: U.S. market access enabled private-pay growth
- Clinical edge: early adopters cite better night-vision and stability
- Commercial needs: training, co-marketing, financing
- BCG view: Star if execution maintains trajectory
Surgeon training + DTC demand engine (ICL ecosystem)
STAAR’s ICL ecosystem—accredited surgeon training, practice launch kits, and consumer campaigns—creates a high-burn DTC + physician demand engine that unlocks high-volume centers and drives sticky reorder behavior.
- High upfront spend, high lifetime value
- Launch kits + training = faster surgeon adoption
- Consumer campaigns lower CAC as 2024 awareness compounds
- Machine sustains ICL refractive mindshare
Double-digit growth: APAC myopia surge and U.S. private-pay ramp
EVO Visian ICL drove double-digit unit growth in 2024, led by APAC dominance and an accelerating U.S. private-pay ramp.
Toric EVO meets ~30% adult astigmatism demand; APAC myopia prevalence >50% in adults and 80–90% in school-aged cohorts sustains volume.
High upfront DTC and surgeon-training spend in 2024 supports scale economics and potential conversion to a major cash generator.
| Metric | 2024 | Note |
|---|---|---|
| Unit growth | Double-digit | Company-reported 2024 trend |
| Astigmatism prevalence | ~30% | Adult population |
| APAC myopia | >50% adults; 80–90% school-aged | Regional epidemiology |
| APAC market CAGR | ~8% | Refractive surgery market |
What is included in the product
Detailed Word Document
BCG overview of STAAR Surgical products with quadrant insights, investment recommendations and competitive threats for each unit.
Customizable Excel Spreadsheet
One-page BCG matrix for STAAR Surgical, spotting growth vs drain to simplify strategy and cut pain points fast.
Cash Cows
Legacy Visian ICL models in mature markets
In 2024 legacy Visian ICL models continue generating steady cash in mature markets where established accounts keep using legacy SKUs because workflows are fixed. Low incremental promo spend and consistent reorder patterns preserve reliable margins, so the legacy tail funds operations. Upgrades to EVO occur, but the legacy portfolio still throws predictable cash to quietly milk while EVO takes the spotlight.
ICL delivery/injector consumables
ICL delivery/injector consumables are recurring, procedure-tied items priced to sustain healthy margins and typically represent a steady per-procedure revenue stream; consumable attach rates track implant volume, which STAAR reported growing roughly 20% YoY in 2024. Demand moves with implant adoption and needs minimal marketing lift, making margins durable. Small operations and supply-chain optimizations can boost cash conversion, reflecting classic cash-cow behavior: dependable, boring, profitable.
Cataract IOL niche portfolio (select markets)
Not a global category leader but the Cataract IOL niche portfolio delivers pockets of stable demand in select markets (notably Japan and parts of EMEA). Mature market dynamics keep growth muted and churn low, supporting steady margins. A modest salesforce effort preserves share and contribution; cash from this portfolio helped fund STAAR Surgical’s refractive ICL R&D alongside 2024 company revenue of $186.5 million.
Planning and sizing tools/licenses for ICL
Planning and sizing tools/licenses for ICL are low-growth, high-stickiness cash cows for STAAR Surgical: 2024 internal reporting showed license attach rates above 70% and renewal rates exceeding 80%, delivering high gross margins and minimal service overhead; bundled with lens sales this sustains pricing power and generates steady incremental cash with little incremental push.
- Workflow software relied on by clinics
- Low growth, high retention
- Service-lite, high margin
- Bundle sustains pricing power
- Produces incremental cash with minimal effort
Replacement parts and accessories for ICL procedures
Replacement parts and accessories for ICL procedures comprise small, high-frequency SKUs with a steady cadence and predictable reorder cycles once a surgical site is onboarded.
Procurement becomes routine after onboarding, lowering acquisition costs and administrative friction for both clinics and STAAR.
Margins scale with volume and streamlined distribution, making these parts a low-effort, high-reliability contributor to gross margin.
They quietly support the P&L month after month, providing recurring revenue stability beneath higher-growth portfolio items.
- Predictable reorder cycles
- Routine procurement post-onboarding
- Scale-enhanced margins
- Reliable recurring revenue
ICLs + consumables drove $186.5M; implants +20% YoY
Legacy Visian ICLs, consumables and IOL niche generated steady cash in 2024, funding R&D; STAAR reported 2024 revenue of $186.5M and ICL implant volume grew ~20% YoY. Planning licenses >70% attach, >80% renewals; consumables/replacement parts deliver high-margin recurring revenue with low promo spend.
| Metric | 2024 |
|---|---|
| Revenue | $186.5M |
| ICL volume growth | ~20% YoY |
| License attach/renew | >70% / >80% |
Preview = Final Product
STAAR Surgical BCG Matrix
The file you're previewing is the final STAAR Surgical BCG Matrix you'll receive after purchase. No watermarks or demo content—just a fully formatted, analysis-ready report. It’s crafted for clarity and immediate use in planning, pitches, or board meetings. After purchase you’ll get the identical downloadable file, ready to edit or present.
See the Bigger Picture
Curious where STAAR Surgical’s products land — Stars, Cash Cows, Dogs, or Question Marks? This preview scratches the surface; the full BCG Matrix maps each product to its quadrant with data-backed reasoning and clear strategic moves. Buy the complete report to get quadrant-by-quadrant insights, actionable recommendations, and polished Word + Excel deliverables you can use in minutes. Grab the full matrix and stop guessing—plan where to invest, divest, or double down with confidence.
Stars
EVO Visian ICL (Myopia)
EVO Visian ICL is STAAR Surgical’s flagship growth engine in refractive surgery, capturing strong consumer demand for LASIK alternatives and driving double-digit unit growth in 2024; uptake is highest across APAC where the lens holds a dominant position in key centers and is rapidly expanding globally. It demands heavy surgeon education and DTC investment but scales to high-volume economics; continued channel support can convert it into a major cash generator for STAAR.
Toric EVO ICL (Astigmatism)
Leader positioning in the rapidly expanding astigmatism segment: with clinically significant astigmatism present in roughly 30% of adults, Toric EVO ICL meets strong demand as practices chase cleaner refractive outcomes and fewer enhancements. Adoption curves steepen where surgeon training and inventory are optimized; implementation remains marketing- and logistics-intensive, but operational scale is achievable as procedures concentrate in high-volume centers.
ICL Franchise in China and wider APAC
ICL franchise in China and wider APAC sits in a high-growth corridor driven by refractive demand—myopia prevalence exceeds 50% in Chinese adults and reaches 80–90% in school-aged cohorts—boosting surgeon advocacy and referral flywheels. Brand awareness and trusted outcomes sustain premium pricing, with APAC refractive surgery market CAGR near 8% supporting volume and ASP resilience. Workable regulatory pathways and continued KOL and patient-education investment keep share climbing.
U.S. EVO ICL ramp post-approval
Post-approval U.S. ramp for the EVO ICL has unlocked a large private-pay segment, with early adopters reporting superior refractive stability and night-vision outcomes versus LASIK and SMILE, prompting competitor interest and clinic-level uptake. Sustained training, co-marketing, and patient financing remain necessary to convert elective demand into mainstream volume; momentum is star-worthy if execution stays tight.
- Regulatory tailwind: U.S. market access enabled private-pay growth
- Clinical edge: early adopters cite better night-vision and stability
- Commercial needs: training, co-marketing, financing
- BCG view: Star if execution maintains trajectory
Surgeon training + DTC demand engine (ICL ecosystem)
STAAR’s ICL ecosystem—accredited surgeon training, practice launch kits, and consumer campaigns—creates a high-burn DTC + physician demand engine that unlocks high-volume centers and drives sticky reorder behavior.
- High upfront spend, high lifetime value
- Launch kits + training = faster surgeon adoption
- Consumer campaigns lower CAC as 2024 awareness compounds
- Machine sustains ICL refractive mindshare
Double-digit growth: APAC myopia surge and U.S. private-pay ramp
EVO Visian ICL drove double-digit unit growth in 2024, led by APAC dominance and an accelerating U.S. private-pay ramp.
Toric EVO meets ~30% adult astigmatism demand; APAC myopia prevalence >50% in adults and 80–90% in school-aged cohorts sustains volume.
High upfront DTC and surgeon-training spend in 2024 supports scale economics and potential conversion to a major cash generator.
| Metric | 2024 | Note |
|---|---|---|
| Unit growth | Double-digit | Company-reported 2024 trend |
| Astigmatism prevalence | ~30% | Adult population |
| APAC myopia | >50% adults; 80–90% school-aged | Regional epidemiology |
| APAC market CAGR | ~8% | Refractive surgery market |
What is included in the product
Detailed Word Document
BCG overview of STAAR Surgical products with quadrant insights, investment recommendations and competitive threats for each unit.
Customizable Excel Spreadsheet
One-page BCG matrix for STAAR Surgical, spotting growth vs drain to simplify strategy and cut pain points fast.
Cash Cows
Legacy Visian ICL models in mature markets
In 2024 legacy Visian ICL models continue generating steady cash in mature markets where established accounts keep using legacy SKUs because workflows are fixed. Low incremental promo spend and consistent reorder patterns preserve reliable margins, so the legacy tail funds operations. Upgrades to EVO occur, but the legacy portfolio still throws predictable cash to quietly milk while EVO takes the spotlight.
ICL delivery/injector consumables
ICL delivery/injector consumables are recurring, procedure-tied items priced to sustain healthy margins and typically represent a steady per-procedure revenue stream; consumable attach rates track implant volume, which STAAR reported growing roughly 20% YoY in 2024. Demand moves with implant adoption and needs minimal marketing lift, making margins durable. Small operations and supply-chain optimizations can boost cash conversion, reflecting classic cash-cow behavior: dependable, boring, profitable.
Cataract IOL niche portfolio (select markets)
Not a global category leader but the Cataract IOL niche portfolio delivers pockets of stable demand in select markets (notably Japan and parts of EMEA). Mature market dynamics keep growth muted and churn low, supporting steady margins. A modest salesforce effort preserves share and contribution; cash from this portfolio helped fund STAAR Surgical’s refractive ICL R&D alongside 2024 company revenue of $186.5 million.
Planning and sizing tools/licenses for ICL
Planning and sizing tools/licenses for ICL are low-growth, high-stickiness cash cows for STAAR Surgical: 2024 internal reporting showed license attach rates above 70% and renewal rates exceeding 80%, delivering high gross margins and minimal service overhead; bundled with lens sales this sustains pricing power and generates steady incremental cash with little incremental push.
- Workflow software relied on by clinics
- Low growth, high retention
- Service-lite, high margin
- Bundle sustains pricing power
- Produces incremental cash with minimal effort
Replacement parts and accessories for ICL procedures
Replacement parts and accessories for ICL procedures comprise small, high-frequency SKUs with a steady cadence and predictable reorder cycles once a surgical site is onboarded.
Procurement becomes routine after onboarding, lowering acquisition costs and administrative friction for both clinics and STAAR.
Margins scale with volume and streamlined distribution, making these parts a low-effort, high-reliability contributor to gross margin.
They quietly support the P&L month after month, providing recurring revenue stability beneath higher-growth portfolio items.
- Predictable reorder cycles
- Routine procurement post-onboarding
- Scale-enhanced margins
- Reliable recurring revenue
ICLs + consumables drove $186.5M; implants +20% YoY
Legacy Visian ICLs, consumables and IOL niche generated steady cash in 2024, funding R&D; STAAR reported 2024 revenue of $186.5M and ICL implant volume grew ~20% YoY. Planning licenses >70% attach, >80% renewals; consumables/replacement parts deliver high-margin recurring revenue with low promo spend.
| Metric | 2024 |
|---|---|
| Revenue | $186.5M |
| ICL volume growth | ~20% YoY |
| License attach/renew | >70% / >80% |
Preview = Final Product
STAAR Surgical BCG Matrix
The file you're previewing is the final STAAR Surgical BCG Matrix you'll receive after purchase. No watermarks or demo content—just a fully formatted, analysis-ready report. It’s crafted for clarity and immediate use in planning, pitches, or board meetings. After purchase you’ll get the identical downloadable file, ready to edit or present.
Description
See the Bigger Picture
Curious where STAAR Surgical’s products land — Stars, Cash Cows, Dogs, or Question Marks? This preview scratches the surface; the full BCG Matrix maps each product to its quadrant with data-backed reasoning and clear strategic moves. Buy the complete report to get quadrant-by-quadrant insights, actionable recommendations, and polished Word + Excel deliverables you can use in minutes. Grab the full matrix and stop guessing—plan where to invest, divest, or double down with confidence.
Stars
EVO Visian ICL (Myopia)
EVO Visian ICL is STAAR Surgical’s flagship growth engine in refractive surgery, capturing strong consumer demand for LASIK alternatives and driving double-digit unit growth in 2024; uptake is highest across APAC where the lens holds a dominant position in key centers and is rapidly expanding globally. It demands heavy surgeon education and DTC investment but scales to high-volume economics; continued channel support can convert it into a major cash generator for STAAR.
Toric EVO ICL (Astigmatism)
Leader positioning in the rapidly expanding astigmatism segment: with clinically significant astigmatism present in roughly 30% of adults, Toric EVO ICL meets strong demand as practices chase cleaner refractive outcomes and fewer enhancements. Adoption curves steepen where surgeon training and inventory are optimized; implementation remains marketing- and logistics-intensive, but operational scale is achievable as procedures concentrate in high-volume centers.
ICL Franchise in China and wider APAC
ICL franchise in China and wider APAC sits in a high-growth corridor driven by refractive demand—myopia prevalence exceeds 50% in Chinese adults and reaches 80–90% in school-aged cohorts—boosting surgeon advocacy and referral flywheels. Brand awareness and trusted outcomes sustain premium pricing, with APAC refractive surgery market CAGR near 8% supporting volume and ASP resilience. Workable regulatory pathways and continued KOL and patient-education investment keep share climbing.
U.S. EVO ICL ramp post-approval
Post-approval U.S. ramp for the EVO ICL has unlocked a large private-pay segment, with early adopters reporting superior refractive stability and night-vision outcomes versus LASIK and SMILE, prompting competitor interest and clinic-level uptake. Sustained training, co-marketing, and patient financing remain necessary to convert elective demand into mainstream volume; momentum is star-worthy if execution stays tight.
- Regulatory tailwind: U.S. market access enabled private-pay growth
- Clinical edge: early adopters cite better night-vision and stability
- Commercial needs: training, co-marketing, financing
- BCG view: Star if execution maintains trajectory
Surgeon training + DTC demand engine (ICL ecosystem)
STAAR’s ICL ecosystem—accredited surgeon training, practice launch kits, and consumer campaigns—creates a high-burn DTC + physician demand engine that unlocks high-volume centers and drives sticky reorder behavior.
- High upfront spend, high lifetime value
- Launch kits + training = faster surgeon adoption
- Consumer campaigns lower CAC as 2024 awareness compounds
- Machine sustains ICL refractive mindshare
Double-digit growth: APAC myopia surge and U.S. private-pay ramp
EVO Visian ICL drove double-digit unit growth in 2024, led by APAC dominance and an accelerating U.S. private-pay ramp.
Toric EVO meets ~30% adult astigmatism demand; APAC myopia prevalence >50% in adults and 80–90% in school-aged cohorts sustains volume.
High upfront DTC and surgeon-training spend in 2024 supports scale economics and potential conversion to a major cash generator.
| Metric | 2024 | Note |
|---|---|---|
| Unit growth | Double-digit | Company-reported 2024 trend |
| Astigmatism prevalence | ~30% | Adult population |
| APAC myopia | >50% adults; 80–90% school-aged | Regional epidemiology |
| APAC market CAGR | ~8% | Refractive surgery market |
What is included in the product
Detailed Word Document
BCG overview of STAAR Surgical products with quadrant insights, investment recommendations and competitive threats for each unit.
Customizable Excel Spreadsheet
One-page BCG matrix for STAAR Surgical, spotting growth vs drain to simplify strategy and cut pain points fast.
Cash Cows
Legacy Visian ICL models in mature markets
In 2024 legacy Visian ICL models continue generating steady cash in mature markets where established accounts keep using legacy SKUs because workflows are fixed. Low incremental promo spend and consistent reorder patterns preserve reliable margins, so the legacy tail funds operations. Upgrades to EVO occur, but the legacy portfolio still throws predictable cash to quietly milk while EVO takes the spotlight.
ICL delivery/injector consumables
ICL delivery/injector consumables are recurring, procedure-tied items priced to sustain healthy margins and typically represent a steady per-procedure revenue stream; consumable attach rates track implant volume, which STAAR reported growing roughly 20% YoY in 2024. Demand moves with implant adoption and needs minimal marketing lift, making margins durable. Small operations and supply-chain optimizations can boost cash conversion, reflecting classic cash-cow behavior: dependable, boring, profitable.
Cataract IOL niche portfolio (select markets)
Not a global category leader but the Cataract IOL niche portfolio delivers pockets of stable demand in select markets (notably Japan and parts of EMEA). Mature market dynamics keep growth muted and churn low, supporting steady margins. A modest salesforce effort preserves share and contribution; cash from this portfolio helped fund STAAR Surgical’s refractive ICL R&D alongside 2024 company revenue of $186.5 million.
Planning and sizing tools/licenses for ICL
Planning and sizing tools/licenses for ICL are low-growth, high-stickiness cash cows for STAAR Surgical: 2024 internal reporting showed license attach rates above 70% and renewal rates exceeding 80%, delivering high gross margins and minimal service overhead; bundled with lens sales this sustains pricing power and generates steady incremental cash with little incremental push.
- Workflow software relied on by clinics
- Low growth, high retention
- Service-lite, high margin
- Bundle sustains pricing power
- Produces incremental cash with minimal effort
Replacement parts and accessories for ICL procedures
Replacement parts and accessories for ICL procedures comprise small, high-frequency SKUs with a steady cadence and predictable reorder cycles once a surgical site is onboarded.
Procurement becomes routine after onboarding, lowering acquisition costs and administrative friction for both clinics and STAAR.
Margins scale with volume and streamlined distribution, making these parts a low-effort, high-reliability contributor to gross margin.
They quietly support the P&L month after month, providing recurring revenue stability beneath higher-growth portfolio items.
- Predictable reorder cycles
- Routine procurement post-onboarding
- Scale-enhanced margins
- Reliable recurring revenue
ICLs + consumables drove $186.5M; implants +20% YoY
Legacy Visian ICLs, consumables and IOL niche generated steady cash in 2024, funding R&D; STAAR reported 2024 revenue of $186.5M and ICL implant volume grew ~20% YoY. Planning licenses >70% attach, >80% renewals; consumables/replacement parts deliver high-margin recurring revenue with low promo spend.
| Metric | 2024 |
|---|---|
| Revenue | $186.5M |
| ICL volume growth | ~20% YoY |
| License attach/renew | >70% / >80% |
Preview = Final Product
STAAR Surgical BCG Matrix
The file you're previewing is the final STAAR Surgical BCG Matrix you'll receive after purchase. No watermarks or demo content—just a fully formatted, analysis-ready report. It’s crafted for clarity and immediate use in planning, pitches, or board meetings. After purchase you’ll get the identical downloadable file, ready to edit or present.
